» Articles » PMID: 39062091

Interactions Involving Glycine and Other Amino Acid Neurotransmitters: Focus on Transporter-Mediated Regulation of Release and Glycine-Glutamate Crosstalk

Overview
Journal Biomedicines
Date 2024 Jul 27
PMID 39062091
Authors
Affiliations
Soon will be listed here.
Abstract

Glycine plays a pivotal role in the Central Nervous System (CNS), being a major inhibitory neurotransmitter as well as a co-agonist of Glutamate at excitatory NMDA receptors. Interactions involving Glycine and other neurotransmitters are the subject of different studies. Functional interactions among neurotransmitters include the modulation of release through release-regulating receptors but also through transporter-mediated mechanisms. Many transporter-mediated interactions involve the amino acid transmitters Glycine, Glutamate, and GABA. Different studies published during the last two decades investigated a number of transporter-mediated interactions in depth involving amino acid transmitters at the nerve terminal level in different CNS areas, providing details of mechanisms involved and suggesting pathophysiological significances. Here, this evidence is reviewed also considering additional recent information available in the literature, with a special (but not exclusive) focus on glycinergic neurotransmission and Glycine-Glutamate interactions. Some possible pharmacological implications, although partly speculative, are also discussed. Dysregulations in glycinergic and glutamatergic transmission are involved in relevant CNS pathologies. Pharmacological interventions on glycinergic targets (including receptors and transporters) are under study to develop novel therapies against serious CNS pathological states including pain, schizophrenia, epilepsy, and neurodegenerative diseases. Although with limitations, it is hoped to possibly contribute to a better understanding of the complex interactions between glycine-mediated neurotransmission and other major amino acid transmitters, also in view of the current interest in potential drugs acting on "glycinergic" targets.

Citing Articles

Novel pharmaceutical treatment approaches for schizophrenia: a systematic literature review.

Jarab A, Al-Qerem W, Khdour A, Awadallah H, Mimi Y, Khdour M Eur J Clin Pharmacol. 2025; .

PMID: 39951117 DOI: 10.1007/s00228-025-03809-7.


Glycine Transporter 1 Inhibitors Minimize the Analgesic Tolerance to Morphine.

Galambos A, Essmat N, Lakatos P, Szucs E, Boldizsar Jr I, Abbood S Int J Mol Sci. 2024; 25(20).

PMID: 39456918 PMC: 11508341. DOI: 10.3390/ijms252011136.

References
1.
Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W . The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006; 1762(11-12):1068-82. DOI: 10.1016/j.bbadis.2006.05.002. View

2.
Raiteri L, Stigliani S, Usai C, Diaspro A, Paluzzi S, Milanese M . Functional expression of release-regulating glycine transporters GLYT1 on GABAergic neurons and GLYT2 on astrocytes in mouse spinal cord. Neurochem Int. 2007; 52(1-2):103-12. DOI: 10.1016/j.neuint.2007.04.027. View

3.
Cioffi C . Inhibition of Glycine Re-Uptake: A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling. Biomolecules. 2021; 11(6). PMC: 8230656. DOI: 10.3390/biom11060864. View

4.
Lu L, Chang W, Mao Y, Cheng M, Zhuang X, Kuo C . The Development of a Regulator of Human Serine Racemase for N-Methyl-D-aspartate Function. Biomedicines. 2024; 12(4). PMC: 11048566. DOI: 10.3390/biomedicines12040853. View

5.
Bonifacino T, Musazzi L, Milanese M, Seguini M, Marte A, Gallia E . Altered mechanisms underlying the abnormal glutamate release in amyotrophic lateral sclerosis at a pre-symptomatic stage of the disease. Neurobiol Dis. 2016; 95:122-33. DOI: 10.1016/j.nbd.2016.07.011. View